MODEYSO Approval Sets Multi-Trial Bar for Pediatric CNS Submissions

Jazz Pharmaceuticals secured FDA accelerated approval for MODEYSO (dordaviprone) on August 6, 2025, establishing a five-trial evidence package as the regulatory foundation for a rare pediatric and adult CNS indication. For regulatory affairs leads and QA directors navigating accelerated approval pathways in oncology, the architecture of this submission signals how multi-study pooled efficacy data can satisfy FDA requirements where single-trial enrollment is constrained by disease rarity.

MODEYSO is indicated for adult and pediatric patients aged 1 year and older with diffuse midline glioma harboring an H3 K27M mutation with progressive disease following prior therapy. The accelerated approval was supported by five clinical trials -- ONC006, ONC013, ONC014, ONC016, and ONC018 -- conducted across 68 U.S. sites. Efficacy was assessed in 50 patients using overall response rate (ORR) and duration of response (DOR) by blinded independent central review (BICR) against brain tumor-specific response criteria. Safety was evaluated in a broader population of 376 patients across four of the five trials.

The safety population's age distribution warrants attention from manufacturing and QA teams: 30% of the 376-patient safety cohort were aged 2 to 11, and 11% were 12 to 17, meaning pediatric-specific GMP considerations -- including weight-based dosing and flexible oral formulation requirements -- are central to the product's commercial execution. MODEYSO is administered orally once weekly, with capsule contents dispersible in water, apple juice, lemonade, or sports drink for patients unable to swallow capsules whole.

The demographic composition of both the efficacy and safety populations reflects ongoing industry scrutiny around trial diversity. In the efficacy cohort, 80% of patients were White and 8% Hispanic or Latino; in the larger safety population, 74% were White and 13% Hispanic or Latino. These figures will inform post-approval commitments and label language as FDA continues to apply its diversity action plan framework to rare disease submissions.

Source: FDA Drug Trials Snapshots -- MODEYSO, published April 28, 2026, based on original approval date of August 6, 2025. All data sourced directly from the FDA Snapshot document.